Standard versus intensive therApy by Rosuvastatin for lipiD lowering

Not Applicable

• Conditions: Hyperlipemia

• Registration Number: JPRN-UMIN000006796
• Lead Sponsor: Department of Cardiovascular medicine, Saga University Faculty of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-12-01
• Study Completion: 2012-12-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients whom Rosuvastatin has already been prescribed 2) Familial hyperlipidemia or Secondary hyperlipemia 3) Patients with a history of hypersensitivity to statin 4) Patients who showed the symptoms of cerebrovascular disorder within 3months 5) Patients who showed the symptoms of myocardial infarction within 3 months 6) Patients diagnosed active liver disease(ALT or AST > 100 IU/L, T-bil > 2.5 mg/dL) 7) Patients with severe kidney dysfunction and also patients with poor control of kidney dysfunction 8)serum CK > 500 IU/L 9) Patients who are prescribing cyclosporin 10) Pregnant or lactating women 11) Decreased thyroid activity, A hereditary line disease(Muscular dystrophy etc) or patients with the family history, patients with the anamnesis of drug-induced muscle disorder 12) Drug abuse and/or patients of alcoholism 13)Patients who are considered not eligible for the study by the attending doctor due to other reasons

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
change of the inflammation marker at the time of registration and 12 weeks after. (Hs-CRP,RLP-cholesterol,MDA-LDL,small dense LDL,HMW-adioponectin,RAGE)

Secondary Outcome Measures

Name	Time	Method
The serum lipid improvement effect of 4 weeks and 12 weeks after. (LDL-cholesterol,TG,HDL-cholesterol, LDL/HDL ratio)